AstraZeneca and Amgen’s tezepelumab competitor Tezspire moved closer to expanding into eosinophilic esophagitis (EoE) after meeting Phase 3 goals. An eventual approval would give the therapy a third indication and directly target a market where Dupixent is the only approved biologic option. The EoE setting matters commercially and clinically: EoE is chronic, and the therapy class has been positioned as a potential blockbuster opportunity if regulatory agencies greenlight the new use. The Phase 3 success also increases pressure on competitors to differentiate by efficacy, safety, and patient subgroups. For AstraZeneca and Amgen, the next step is regulatory review; the Phase 3 readout strengthens the case for broader uptake if dosing and endpoints translate to real-world treatment patterns.